Display options
Cite
Chen JH, Yu HJ, Hsu C, et al. Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Transl Oncol. 2015;8(3):204-9doi: 10.1016/j.tranon.2015.04.001.
Chen, J. H., Yu, H. J., Hsu, C., Mehta, R. S., Carpenter, P. M., & Su, M. Y. (2015). Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Translational oncology, 8(3), 204-9. https://doi.org/10.1016/j.tranon.2015.04.001
Chen, Jeon Hor, et al. "Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy." Translational oncology vol. 8,3 (2015): 204-9. doi: https://doi.org/10.1016/j.tranon.2015.04.001
Chen JH, Yu HJ, Hsu C, Mehta RS, Carpenter PM, Su MY. Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Transl Oncol. 2015 Jun;8(3):204-9. doi: 10.1016/j.tranon.2015.04.001. PMID: 26055178; PMCID: PMC4487259.
Copy Download .nbib Format: NLM
Share it on

Transl Oncol. 2015 Jun;8(3):204-9. doi: 10.1016/j.tranon.2015.04.001.

Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.

Translational oncology

Jeon Hor Chen, Hon J Yu, Christine Hsu, Rita S Mehta, Philip M Carpenter, Min Ying Su

Affiliations

  1. Center for Functional Onco-Imaging, Department of Radiological Sciences, University of California, Irvine, Irvine, CA, USA; Department of Radiology, E-Da Hospital and I-Shou University, Kaohsiung, Taiwan. Electronic address: [email protected].
  2. Center for Functional Onco-Imaging, Department of Radiological Sciences, University of California, Irvine, Irvine, CA, USA.
  3. Department of Medicine, University of California, Irvine, Irvine, CA, USA.
  4. Department of Pathology, University of California, Irvine, Irvine, CA, USA.

PMID: 26055178 PMCID: PMC4487259 DOI: 10.1016/j.tranon.2015.04.001

Abstract

PURPOSE: This study investigated the association between background parenchymal enhancement (BPE) and pathologic response to neoadjuvant chemotherapy (NAC).

METHODS: A total of 46 patients diagnosed with invasive breast cancer were analyzed. Each patient had three magnetic resonance imaging (MRI) studies, one pre-treatment and two follow-up (F/U) MRI studies. BPE was measured as the averaged enhancement of the whole fibroglandular tissues. The pre-treatment BPE and the changes in the F/U MRI were compared between patients achieving pathologic complete response (pCR) versus those not. Subgroup analyses based on age, estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) status of their cancers were also performed.

RESULTS: The pre-treatment BPE was higher in the pCR group than that in the non-pCR group. Compared to baseline, BPE at F/U-1 was significantly decreased in the pCR group but not in the non-pCR group. In subgroup analysis based on age, these results were seen only in the younger group (<55 years old), not in the older group (≥55 years old). Older patients had a significantly lower pre-treatment BPE than younger patients. In analysis based on molecular biomarkers, a significantly decreased BPE at F/U-1 was only found in the ER-negative pCR group but not in the non-pCR, nor in the ER-positive groups.

CONCLUSIONS: A higher pre-treatment BPE showing a significant decrease early after starting NAC was related to pCR in pre/peri-menopausal patients.

Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

References

  1. J Magn Reson Imaging. 2011 May;33(5):1229-34 - PubMed
  2. Acta Radiol. 2009 Nov;50(9):990-8 - PubMed
  3. Magn Reson Imaging Clin N Am. 2013 Aug;21(3):483-93 - PubMed
  4. Magn Reson Imaging Clin N Am. 1994 Nov;2(4):633-58 - PubMed
  5. Eur Radiol. 2010 Jul;20(7):1563-71 - PubMed
  6. Radiology. 2014 Mar;270(3):699-707 - PubMed
  7. Cancer Res. 2003 Jun 1;63(11):2723-7 - PubMed
  8. J Clin Oncol. 2005 Sep 1;23(25):6002-8 - PubMed
  9. Eur Radiol. 2011 Jul;21(7):1374-82 - PubMed
  10. Cancer. 2008 Jan 1;112(1):17-26 - PubMed
  11. Breast J. 2005 Jul-Aug;11(4):236-41 - PubMed
  12. Eur J Cancer. 1998 Apr;34(5):632-40 - PubMed
  13. Breast Cancer. 2012 Jul;19(3):259-65 - PubMed
  14. Rofo. 2011 May;183(5):441-7 - PubMed
  15. J Clin Oncol. 2001 Feb 15;19(4):1195-206 - PubMed
  16. Eur J Radiol. 2012 Jul;81(7):1539-42 - PubMed
  17. J Clin Oncol. 2012 May 20;30(15):1796-804 - PubMed
  18. NMR Biomed. 2002 Apr;15(2):154-63 - PubMed
  19. Clin Cancer Res. 2008 Oct 15;14(20):6580-9 - PubMed
  20. Radiology. 1997 Apr;203(1):145-9 - PubMed
  21. Eur J Radiol. 2006 Nov;60(2):270-4 - PubMed
  22. Eur Radiol. 2011 Nov;21(11):2261-7 - PubMed
  23. Breast J. 2012 Nov-Dec;18(6):527-34 - PubMed
  24. J Magn Reson Imaging. 2012 Jul;36(1):145-51 - PubMed
  25. Med Phys. 2008 Dec;35(12):5253-62 - PubMed
  26. Magn Reson Imaging. 2013 Nov;31(9):1465-71 - PubMed
  27. AJR Am J Roentgenol. 2008 Jun;190(6):1630-6 - PubMed
  28. Radiology. 1997 Apr;203(1):137-44 - PubMed

Publication Types

Grant support